Copyright
©The Author(s) 2019.
World J Nephrol. Oct 27, 2019; 8(6): 95-108
Published online Oct 27, 2019. doi: 10.5527/wjn.v8.i6.95
Published online Oct 27, 2019. doi: 10.5527/wjn.v8.i6.95
Table 4 Malignancies
| ABO-incompatible (n = 27) | ABO-compatible (n = 108) | P value | ||
| % of patients with a (pre)malignancy | 22.2 | 7.4 | 0.01 | |
| Solid organ, (%) | 11 | 2.8 | ||
| Lymphoma, (%) | 0 | 1.9 | ||
| Skin malignancy, (%) | 3.7 | 1.9 | ||
| Melanoma, (%) | 3.7 | 0 | ||
| Premalignant lesion, (%) | 3.7 | 0.9 | ||
| % of patients dying from their malignancy | 0 | 38 | 0.09 | |
- Citation: van Sandwijk MS, Klooster A, ten Berge IJ, Diepstra A, Florquin S, Hoelbeek JJ, Bemelman FJ, Sanders JS. Complement activation and long-term graft function in ABO-incompatible kidney transplantation. World J Nephrol 2019; 8(6): 95-108
- URL: https://www.wjgnet.com/2220-6124/full/v8/i6/95.htm
- DOI: https://dx.doi.org/10.5527/wjn.v8.i6.95